Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||Carboplatin + Paclitaxel + RO4929097||Phase I||Actionable||In a Phase I trial, the combination of RO4929097 (RG-4733), Paraplatin (carboplatin), and Taxol (paclitaxel) demonstrated safety and resulted in a pathologic complete response in 36% (5/14) of patients with triple receptor-negative breast cancer; however, this trial as well as further development of RO4929097 (RG-4733) were discontinued due to the limited clinical efficacy observed in other cancer types (PMID: 31953695).||31953695|